Off-label psychopharmacologic prescribing for children: History supports close clinical monitoring

被引：65

作者：

Zito J.M. ^{[1
]}

Derivan A.T. ^{[2
]}

Kratochvil C.J. ^{[3
]}

Safer D.J. ^{[4
]}

Fegert J.M. ^{[5
]}

Greenhill L.L. ^{[6
]}

机构：

[1] Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland, Baltimore, MD

[2] Department of Psychiatry and Human Behavior, Thomas Jefferson University School of Medicine, Philadelphia, PA

[3] Psychopharmacology Research Center, University of Nebraska Medical Center, Omaha, NE

[4] Department of Psychiatry, Johns Hopkins Medical Institutions, Baltimore, MD

[5] Department of Child and Adolescent Psychiatry/Psychotherapy, University Hospital Ulm, Ulm

[6] Department of Psychiatry, Columbia University Medical Center, New York, NY

来源：

Child and Adolescent Psychiatry and Mental Health | / 2卷 / 1期

关键词：

Therapeutic Drug Monitoring; Guanfacine; Pemoline; Primary Nocturnal Enuresis; Retrolental Fibroplasia;

D O I：

10.1186/1753-2000-2-24

中图分类号：

学科分类号：

摘要：

The review presents pediatric adverse drug events from a historical perspective and focuses on selected safety issues associated with off-label use of medications for the psychiatric treatment of youth. Clinical monitoring procedures for major psychotropic drug classes are reviewed. Prior studies suggest that systematic treatment monitoring is warranted so as to both minimize risk of unexpected adverse events and exposures to ineffective treatments. Clinical trials to establish the efficacy and safety of drugs currently being used off-label in the pediatric population are needed. In the meantime, clinicians should consider the existing evidence-base for these drugs and institute close clinical monitoring. © 2008 Zito et al; licensee BioMed Central Ltd.

引用

共 73 条

[1]

Roberts R., Rodriguez W., Murphy D., Crescenzi T., Pediatric drug labeling, JAMA, 290, pp. 905-911, (2003)

[2]

Turner S., Nunn A.J., Choonara I., Unlicensed drug use in children in the UK, The International Journal of Pharmacy, (2004)

[3]

Fost N., Ethical issues in research and innovative therapy in children with mood disorders, Biol Psychiatry, 49, pp. 1015-1022, (2001)

[4]

Behrman R.E., Kliegman R.M., Jenson H.B., Nelson Textbook of Pediatrics, (2003)

[5]

Brunton L.L., Lazo J.S., Parker K.L., Goodman & Gilman's The Pharmacological Basis of Therapeutics, (2006)

[6]

Green W.H., Child and Adolescent Clinical Psychopharmacology, (2007)

[7]

Strom B.L., Pharmacoepidemiology, (2000)

[8]

Kinsey V.E., Zacharias L., Retrolental fibroplasia, JAMA, 139, pp. 572-579, (1949)

[9]

Patz A., The role of oxygen in retrolental fibroplasia, Pediatrics, 19, pp. 504-523, (1957)

[10]

Weiss C.F., Glazko A.J., Weston J.K., Chloramphenicol in the newborn infant, N Engl J Med, 262, pp. 787-794, (1960)

← 1 2 3 4 5 6 7 8 →